AML-M3
We demonstrate the clinical usefulness of a panel of beta2 integrins (CD11a, CD11b and CD11c) in accurate prediction of AML-M3, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.
We demonstrate the clinical usefulness of a panel of beta2 integrins (CD11a, <span class="gene" id="16764927-8-77-82">CD11b</span> and CD11c) in accurate prediction of <span class="disease" id="16764927-8-120-126">AML-M3</span>, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.